Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,500 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma.
Cook J, Johnson I, Higgins A, Sidana S, Warsame R, Gonsalves W, Gertz MA, Buadi F, Lacy M, Kapoor P, Dispenzieri A, Kourelis T, Dingli D, Fonder A, Hayman S, Hobbs M, Hwa YL, Kyle R, Leung N, Go R, Rajkumar VS, Kumar S. Cook J, et al. Am J Hematol. 2021 Mar 1;96(3):330-337. doi: 10.1002/ajh.26074. Epub 2021 Jan 13. Am J Hematol. 2021. PMID: 33326116 Free article.
Prognostic significance of acquired 1q22 gain in multiple myeloma.
Audil HY, Cook JM, Greipp PT, Kapoor P, Baughn LB, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Muchtar E, Siddiqui M, Gonsalves WI, Hwa YL, Leung N, Lin Y, Kourelis TV, Warsame R, Kyle RA, Ketterling RP, Rajkumar SV, Kumar SK. Audil HY, et al. Am J Hematol. 2022 Jan 1;97(1):52-59. doi: 10.1002/ajh.26391. Epub 2021 Nov 3. Am J Hematol. 2022. PMID: 34710241 Free article.
Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.
Cook J, Peng KW, Witzig TE, Broski SM, Villasboas JC, Paludo J, Patnaik M, Rajkumar V, Dispenzieri A, Leung N, Buadi F, Bennani N, Ansell SM, Zhang L, Packiriswamy N, Balakrishnan B, Brunton B, Giers M, Ginos B, Dueck AC, Geyer S, Gertz MA, Warsame R, Go RS, Hayman SR, Dingli D, Kumar S, Bergsagel L, Munoz JL, Gonsalves W, Kourelis T, Muchtar E, Kapoor P, Kyle RA, Lin Y, Siddiqui M, Fonder A, Hobbs M, Hwa L, Naik S, Russell SJ, Lacy MQ. Cook J, et al. Blood Adv. 2022 Jun 14;6(11):3268-3279. doi: 10.1182/bloodadvances.2021006631. Blood Adv. 2022. PMID: 35175355 Free PMC article. Clinical Trial.
Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.
Cook J, Gonsalves WI, Gertz MA, Visram A, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Kapoor P, Kourelis TV, Hayman SR, Kyle RA, Muchtar E, Kumar SK, Hogan WJ, Jacob EK, Buadi FK. Cook J, et al. Bone Marrow Transplant. 2022 Jun;57(6):1007-1009. doi: 10.1038/s41409-022-01659-w. Epub 2022 Apr 2. Bone Marrow Transplant. 2022. PMID: 35368041 No abstract available.
A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncology.
Warsame R, Cook J, Fruth B, Hubbard J, Croghan K, Price KAR, Jatoi A, Kumar S, Thompson C, Buckner J, Dispenzieri A, Sloan J, Dueck AC. Warsame R, et al. Among authors: cook j. Contemp Clin Trials Commun. 2022 Jul 13;29:100964. doi: 10.1016/j.conctc.2022.100964. eCollection 2022 Oct. Contemp Clin Trials Commun. 2022. PMID: 35928285 Free PMC article.
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy.
Ebraheem M, Kumar SK, Dispenzieri A, Jevremovic D, Buadi FK, Dingli D, Cook J, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Binder M, Lin Y, Go RS, Siddiqui MA, Kyle RA, Rajkumar SV, Gonsalves WI, Gertz MA. Ebraheem M, et al. Among authors: cook j. Transplant Cell Ther. 2022 Nov;28(11):760.e1-760.e5. doi: 10.1016/j.jtct.2022.07.030. Epub 2022 Aug 5. Transplant Cell Ther. 2022. PMID: 35940527 Free PMC article.
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL).
Visram A, Hayman SR, Dispenzieri A, Kapoor P, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Warsame R, Kourelis T, Cook J, Binder M, Gonsalves W, Muchtar E, Leung N, Roy V, Rajkumar SV, Kumar S. Visram A, et al. Among authors: cook j. Am J Hematol. 2023 Aug;98(8):1277-1285. doi: 10.1002/ajh.26990. Epub 2023 Jun 19. Am J Hematol. 2023. PMID: 37334773 Clinical Trial.
6,500 results